他莫昔芬片、莱曲唑片治疗乳腺癌引起骨质疏松的临床观察

The clinical observations of tamoxifen and letrozole inducing osteoporosis for treating breast cancer

目的观察他莫昔芬片、莱曲唑内分泌治疗乳腺癌过程中,不良反应引起骨质疏松的差异。方法对绝经后60例乳腺癌患者,随机抽取30例口服他莫昔芬片,30例口服莱曲唑片,分别测口服药0、1、2年时每例患者的骨密度,进行统计学分析。结果口服他莫昔芬片、莱曲唑片1、2年测得骨密度值分别为(0.965±0.021)、(0.923±0.017)、(0.915±0.019)、(0.896±0.013)g/cm2。结论口服他莫昔芬片、莱曲唑片都可使骨密度减低,用药时间越长,骨密度减低越明显;口服莱曲唑片骨密度减低比口服他莫昔芬片使骨密度减低更明显。

Objective To observe the difference between the side effect osteoporosis of tamoxifen and letrozole treating breast cancer. Methods Freely select 30 cases taking TAM and 30 cases taking letrozole of 60 breast cancer cases in postmenopause. To mensurate bone mineral densities （BMD） at 0,1,2 years, then to analyze in statistics. Results To mensnrale BMD in 1,2 years are （0. 965 ± 0. 021 ）g/cm^2, （0. 923 ± 0. 017 ） g/ cm^2, （0.915 ± 0. 019） g/cm^2, （0. 896 ± 0. 013 ）g/cm^2. Conclusion Taking TAM and Letrozole can debase the bone mineral densities. Taking letrozole is laugher than taking TAM.